40320-63-6

Basic information

• Product Name: 1-(Diphenylmethyl)-3-methyl-3-azetidinol
• Synonyms: 1-(Diphenylmethyl)-3-methyl-3-azetidinol;1-benzhydryl-3-Methylazetidin-3-ol;3-Azetidinol, 1-(diphenylMethyl)-3-Methyl-
• CAS NO: 40320-63-6
• Molecular Formula: C₁₇H₁₉NO
• Molecular Weight: 253.33886
• Mol File: 40320-63-6.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 356.45°C at 760 mmHg
• Flash Point: 76.992°C
• Appearance: /
• Density: 1.154g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.62
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(Diphenylmethyl)-3-methyl-3-azetidinol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(Diphenylmethyl)-3-methyl-3-azetidinol(40320-63-6)
• EPA Substance Registry System: 1-(Diphenylmethyl)-3-methyl-3-azetidinol(40320-63-6)

Safety Data

• Hazardous Substances Data: 40320-63-6(Hazardous Substances Data)

Usage

General Description

1-(Diphenylmethyl)-3-methyl-3-azetidinol is a chemical compound with the molecular formula C20H23NO. It belongs to the class of organic compounds known as phenylmethylamines, and is often used as a synthetic intermediate in the pharmaceutical industry. 1-(Diphenylmethyl)-3-methyl-3-azetidinol is derived from diphenylmethanol and is commonly used as a chiral auxiliary in the synthesis of various drugs and pharmaceuticals. It has a unique structure that includes a four-membered azetidine ring, which contributes to its biological and chemical properties. 1-(Diphenylmethyl)-3-methyl-3-azetidinol has potential applications in drug development and as a building block for the synthesis of various pharmaceutical compounds.

InChI:InChI=1/C17H19NO/c1-17(19)12-18(13-17)16(14-8-4-2-5-9-14)15-10-6-3-7-11-15/h2-11,16,19H,12-13H2,1H3

Upstream product

• 40320-60-3 N-benzhydryl 3-azetidinone 
• 75-16-1 methylmagnesium bromide 
• 18621-17-5 1-(diphenylmethyl)-3-hydroxyazetidine 
• 91-00-9 Benzhydrylamine 
• 917-64-6 methyl magnesium iodide 
• 676-58-4 methylmagnesium chloride 

Downstream Products

• 133891-87-9 methanesulfonic acid 1-benzhydryl-3-methylazetidin-3-yl ester 
• 116574-19-7 1-Benzhydryl-3-methyl-3-azetidinyl cyanoacetate 
• 168144-41-0 1-(diphenylmethyl)-3-methoxy-3-methylazetidine 
• 133891-59-5 3-(aminoethyl)-1-(diphenylmethyl)-3-methylazetidine 
• 133891-88-0 1-benzhydryl-3-methylazetidine-3-carbonitrile 
• 133891-60-8 1-(diphenylmethyl)-3-methyl-3-methylaminoazetidine 
• 133891-61-9 3-(dimethylamino)-1-(diphenylmethyl)-3-methylazetidine 
• 133891-52-8 3-amino-1-(diphenylmethyl)-3-methylazetidine 
• 124668-46-8 3-hydroxyl-3-methylazetidine hydrochloride 
• 900511-75-3 1-(diphenylmethyl)-3-(3-fluorophenoxy)-3-methylazetidine 
• 256931-54-1 3-hydroxy-3-methyl azetidine 
• 1227622-79-8 1-benzhydryl-3-[5-bromo-2-(3-chloro-benzyloxy)-phenoxy]-3-methyl-azetidine 
• 1613721-08-6 (R)-6-(1-benzhydryl-3-methylazetidin-3-ylamino)-4-methyl-2,10-dihydro-9-oxa-1,2,4a-triazaphenanthren-3-one 

Relevant articles and documents

SUBSTITUTED PYRAZOLOPYRIMIDINES AS IRAK4 INHIBITORS

The present application relates to novel pyrazolopyrimidine derivatives for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases in humans and in animals, especially of proliferative disorders, autoimmune disorders, metabolic and inflammatory disorders characterized by an overreacting immune system, in particular rheumatological disorders, inflammatory skin disorders, cardiovascular disorders, lung disorders, eye disorders, neurological disorders, pain disorders and cancer, in human as well as of allergic and/or inflammatory diseases in animals, especially of atopic dermatitis and/or Flea Allergy Dermatitis, and especially in domestic animals, particularly in dogs.

Optimized protein kinase Cθ (PKCθ) inhibitors reveal only modest anti-inflammatory efficacy in a rodent model of arthritis

We previously demonstrated that selective inhibition of protein kinase Cθ (PKCθ) with triazinone 1 resulted in dose-dependent reduction of paw swelling in a mouse model of arthritis.1,2 However, a high concentration was required for efficacy, thus providing only a minimal safety window. Herein we describe a strategy to deliver safer compounds based on the hypothesis that optimization of potency in concert with good oral pharmacokinetic (PK) properties would enable in vivo efficacy at reduced exposures, resulting in an improved safety window. Ultimately, transformation of 1 yielded analogues that demonstrated excellent potency and PK properties and fully inhibited IL-2 production in an acute model. In spite of good exposure, twice-a-day treatment with 17l in the glucose-6-phosphate isomerase chronic in vivo mouse model of arthritis yielded only moderate efficacy. On the basis of the exposure achieved, we conclude that PKCθ inhibition alone is insufficient for complete efficacy in this rodent arthritis model.

Tetrahydrochromenoimidazoles as potassium-competitive acid blockers (P-CABs): Structure-activity relationship of their antisecretory properties and their affinity toward the hERG channel

Potassium-competitive acid blockers (P-CABs) constitute a new therapeutic option for the treatment of acid-related diseases that are widespread and constitute a significant economical burden. Enantiomerically pure tetrahydrochromenoimidazoles were prepared using the readily available candidate 4 (BYK 405879) as starting material or the Noyori asymmetric reduction of ketones as key reaction. A comprehensive SAR regarding the influence of the 5-carboxamide and the 8-aryl residue on in vitro activity, acid-suppression in the Ghosh Schild rat, and affinity toward the hERG channel was established. In addition, efficacy and duration of the antisecretory action was examined for the most promising target compounds by 24 h pH-metry in the fistula dog and a significantly different SAR was observed as compared to the Ghosh Schild rat. Several tetrahydrochromenoimidazoles were identified that possessed a comparable profile as the candidate 4.